Anne Kasus-Jacobi to Cataract
This is a "connection" page, showing publications Anne Kasus-Jacobi has written about Cataract.
Connection Strength
1.028
-
N-acetylcarnosine lubricant eyedrops possess all-in-one universal antioxidant protective effects of L-carnosine in aqueous and lipid membrane environments, aldehyde scavenging, and transglycation activities inherent to cataracts: a clinical study of the new vision-saving drug N-acetylcarnosine eyedrop therapy in a database population of over 50,500 patients. Am J Ther. 2009 Nov-Dec; 16(6):517-33.
Score: 0.324
-
N-Acetylcarnosine and histidyl-hydrazide are potent agents for multitargeted ophthalmic therapy of senile cataracts and diabetic ocular complications. J Drug Target. 2009 Jan; 17(1):36-63.
Score: 0.306
-
State of the art clinical efficacy and safety evaluation of N-acetylcarnosine dipeptide ophthalmic prodrug. Principles for the delivery, self-bioactivation, molecular targets and interaction with a highly evolved histidyl-hydrazide structure in the treatment and therapeutic management of a group of sight-threatening eye diseases. Curr Clin Pharmacol. 2009 Jan; 4(1):4-37.
Score: 0.306
-
Novel intraocular and systemic absorption drug delivery and efficacy of N-acetylcarnosine lubricant eye drops or carcinine biologics in pharmaceutical usage and therapeutic vision care. Fundam Clin Pharmacol. 2012 Oct; 26(5):644-78.
Score: 0.091